Neurology
RSSArticles
-
Dapagliflozin Tablets (Farxiga)
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga. -
Effect of Vitamin E and Memantine in Alzheimer's Disease
Among patients with mild-to-moderate Alzheimer's disease, 2000 IU/d of vitamin E resulted in a slower functional decline and a decrease in the caregiver burden. -
Spironolactone for Heart Failure
The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia. -
Influenza
Influenza is possibly the most widespread and well known of infectious diseases. Seasonal epidemics can be found on all continents, and no age segment of the population is untouched. -
Emergency Medicine Reports - Full January 12, 2014 Issue in PDF
-
How Should the Respiratory Muscles be Managed During Critical Illness?
Despite intense research on respiratory muscle physiology and patient-ventilator interfacing, this knowledge has not been integrated into a comprehensive approach toward managing the respiratory muscles in critical illness. This special feature describes the complex array of issues complicating such an endeavor. -
Infectious Disease Malpractice: The $1.2 Million Miscommunication
-
Two-step Screening for Ovarian Cancer: A ‘Scissor-step’ Forward?
-
Improving Adherence: Who's Doing the Work?
Approximately 50% of patients with chronic illnesses do not adhere to indicated medications, treatment regimens, and healthy lifestyle changes.
-
Efficacy of Higher-dose Oseltamivir in Adults with Influenza A and B
In a prospective, open-label, intervention study conducted over four influenza seasons, higher dose oseltamivir compared to standard dose produced no additional benefits in patients with influenza A infection. It did lead to improved virologic response in those with influenza B, but this did not reach statistical significance.